GnC News (1 April, 2020): Human trials for Coronavirus vaccine will begin imminently – but even if they go well and a cure is found, there are many barriers before global immunisation is feasible. (more…)
The day after the first clinical trial of a coronavirus vaccine candidate began in the U.S. on March 16, China announced the first clinical trial of its own coronavirus vaccine candidate, called Ad5-nCoV, jointly developed by Cansino Biologics Inc. and the Academy of Military Medical Sciences of China, based on Cansino’s adenovirus-based viral vector vaccine technology platform, which had been successfully used for developing Ebola virus disease vaccine back in 2017. Ad5-nCoV is a recombinant novel coronavirus vaccine, genetically engineered with the replication-defective adenovirus type 5 as a vector to express the spike protein of the novel coronavirus (SARS-CoV-2).
Novel COVID-19 vaccine and mAb development from spike protein structure: NIH is almost to control the breakthroughChief Editor
NIH Vaccine Research Center and University of Texas (UT) Austin team has uncovered the structure of the COVID-19 spike protein, which mediates viral entry into cells via membrane fusion. It provide complete insight for Novel COVID-19 vaccine and mAb development for the new coronavirus, published in Science Magazine on Wednesday (19 February 2020). (more…)
Oncologic stem cells have been identified in many malignancies, and targeting these cells could help in the fight against cancer. Here are five of the most recent findings regarding cancer stem cells.